Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $868.8 million.

  • Amicus Therapeutics' Liabilities and Shareholders Equity rose 1045.75% to $868.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 735.5%. This contributed to the annual value of $785.0 million for FY2024, which is 91.96% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Liabilities and Shareholders Equity of $868.8 million as of Q3 2025, which was up 1045.75% from $815.3 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Liabilities and Shareholders Equity registered a high of $956.7 million during Q3 2021, and its lowest value of $700.5 million during Q1 2023.
  • In the last 5 years, Amicus Therapeutics' Liabilities and Shareholders Equity had a median value of $786.6 million in 2024 and averaged $792.6 million.
  • Per our database at Business Quant, Amicus Therapeutics' Liabilities and Shareholders Equity soared by 1218.06% in 2021 and then crashed by 2060.75% in 2022.
  • Over the past 5 years, Amicus Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $905.1 million in 2021, then decreased by 19.99% to $724.2 million in 2022, then rose by 7.42% to $777.9 million in 2023, then grew by 0.92% to $785.0 million in 2024, then grew by 10.67% to $868.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $868.8 million for Q3 2025, versus $815.3 million for Q2 2025 and $789.8 million for Q1 2025.